Search results
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
Barrons.com· 2 hours agoWhat began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger...
Why Moderna Stock Rallied Today
Motley Fool· 2 years agoShares of Moderna (NASDAQ: MRNA) jumped 8.4% on Friday after rival drugmaker Pfizer (NYSE: PFE) said it intends to drastically increase the price of its...
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Investor's Business Daily· 7 months agoModerna stock and BioNTech led a sell-off Monday among Covid vaccine makers after Pfizer slashed...
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
Investor's Business Daily· 2 years agoThe Biden administration is planning to stop paying for Covid vaccines and treatments, shifting the...
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
Motley Fool· 8 months agoThe Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster...
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
Zacks via Yahoo Finance· 1 year agoMuch of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers...
Moderna Comes Swinging For Pfizer, GSK In The Mega-Billions RSV Market
Investor's Business Daily· 1 year agoModerna stock rose Wednesday after the biotech said its experimental RSV vaccine proved nearly 84%...
Is Pfizer Stock a Buy Now?
Motley Fool· 2 years agoOver the past year, Pfizer (NYSE: PFE) has been one of the safer stocks to hold. The company has been acquiring businesses to get stronger and more...
Better Bull Market Buy: Pfizer vs. Moderna
Motley Fool via Yahoo Finance· 4 months agoCOVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers...
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
Zacks via Yahoo Finance· 5 months agoPfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are...